http://www.ivi.int

VISION Developing countries free of suffering from infectious disease

MISSION Discover, develop, and deliver safe, effective, and affordable vaccines for the world’s developing nations

GOALS Accelerate development and introduction

of safe and effective vaccines Discover and pursue

proof of concept for new vaccine

candidates

Advance science driving new

achievements in vaccinology

Contribute to building vaccine technology and

systems capacity Cholera Typhoid Dengue / other EDD

GO

AL

-LE

VE

L I

ND

ICA

TO

RS

Shanchol support studies completed

3Q2013 – 4Q2016

Vi-PS impact demonstrated and scale

up introduction

Full scale introduction in Nepal & Pakistan

by 3Q2014

Revised Dengue program strategy defined

By 2Q2013

Next generation cholera vaccine in development

One candidate go/no go by end-2013

Scientific advancements in

vaccinology & immunology published

Three 1st

or 2nd

-tier publications annually

DPRK surveillance in place and JE vaccine introduced nationally

Surveillance by 3Q2014 JE introduced by 2Q2015

Sufficient vaccine supply to enable stockpile &

multiple country introductions

50M doses/year by end-2017

Vi-conjugate development &

introduction progress

2nd

tech transfer by 3Q2013

WHO PQ by 1Q2019

Dengue vaccine development

partnerships established

First by end-2013

Next generation typhoid vaccine(s) in development

Bivalent typhi/paratyphi Ph 1 completed by 3Q2016

Conduct basic research to develop vaccine enhancing

technologies Sublingual dosing

feasibility by end-2014

Ensure technology transfer of portfolio vaccines to

multiple suppliers

2+ mfrs of Cholera and Typhoid Vx by end-2014

Hepatitis E vaccine program

in place

Complete ex-China Clinical trials by 2Q2015

Shigella vaccine program go/no go decision made

One candidate go/no go by end-2014

Conduct basic research to better

understand immunological

responses to vaccines

Malnutrition mouse model by end-2014

NICED study completed by 2Q2015

Tech support relationships with field laboratories

maintained & expanded +2 labs by end-2015

Published evidence to support introduction

decision-making

India investment Case by end-2014

5 country surveillance data by end-2016

Published evidence to support introduction

decision-making

Investment Case by 2Q2013

African surveillance data by 4Q2016

EDD-focused surveillance sites established and generating data

5 countries by end-2017

Conduct feasibility studies to determine disease go/no go decisions

RSV by 1Q2014 Norovirus by end-2015

Improved and expanded vaccinology

course available

By 2014 course date

Korean vaccine manufacturers leveraged to improve supply security and pricing. Korean technology companies leveraged to improve delivery system

SK Chemical partnership established by 3Q2012 Korean tech company partnership by end-2014

Korean research organization partnerships established. Candidates identified and research

programs resourced

1 additional partnership by end-2013 2 candidates by end-2016

Respected post-doc program supporting

Korean scientists in place

8-12 post-docs